Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway

Regenxbio has aggregate cause improvement programs underway. Its RGX-202 cistron therapy merchandise campaigner returned affirmative topline results successful a Phase 3 survey for the attraction of Duchenne. The therapy demonstrated efficacy and was well-tolerated with a favorable information profile. The institution said the topline results enactment plans for imaginable accelerated support of RGX-202 successful 2027.

Regenxbio besides said that it expects to person $100 cardinal successful milestone payments from AbbVie successful transportation with their partnered program. Regenxbio and AbbVie are moving unneurotic to make ABBV-RGX-314 arsenic a attraction for assorted retinal conditions. They are mounting up for Phase 2b/3 trials of ABBV-RGX-314, with dosing expected to statesman successful Q2 2026. The milestone outgo volition beryllium triggered erstwhile the archetypal diligent is dosed successful the Phase 2b study.

Regenxbio Inc (NASDAQ:RGNX) is an American biotech institution based successful Maryland. The institution is focused connected processing cistron therapies for a assortment of uncommon and retinal diseases. It has respective imaginable therapies successful the pipeline, including 1 that targets Duchenne treatment.

While we admit the imaginable of RGNX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 8 Best Middle East and Africa Stocks to Buy According to Hedge Funds and 10 Undervalued Aerospace and Defense Stocks to Buy.

Disclosure: None. Follow Insider Monkey connected Google News.